Delcath jumps 18% as its chemotherapy agent gets orphan drug status

Filed under: Press releases, Products and services

Delcath Systems Inc. (NASDAQ: DCTH), which in pre-market trading shot up 48%, closed the trading session up 18% to close at $3.60 after the FDA granted its chemotherapy agent doxorubicin, used primarily for live cancer an orphan drug status. The Orphan Drug Act was created to encourage and promote research for therapies of rare conditions and diseases that affect less than 200,000 a year in the United States.

Continue reading Delcath jumps 18% as its chemotherapy agent gets orphan drug status

Delcath jumps 18% as its chemotherapy agent gets orphan drug status originally appeared on BloggingStocks on Mon, 31 Aug 2009 17:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Full story at http://www.pheedcontent.com/click.phdo?i=38789cf87fbab19e94927368b478650a